In combination with chemotherapy, the antitumor efficacy of obinutuzumab was superior to that of rituximab, with the elicitation of stronger ADCC due to its binding to both CD16A-158V and 158F, indifferently, in patients suffering from chronic lymphocytic leukemia (CLL) or follicular lymphoma (178–181). Here, FCGR3A is linked to B-cell chronic lymphocytic leukemia.